Laidlaw Reaffirms Buy Rating for Opko Health, Inc. (OPK)

January 3rd, 2017 - By Teresa Graham - 0 comments
Opko Health logoOpko Health, Inc. (NASDAQ:OPK)‘s stock had its “buy” rating reissued by equities research analysts at Laidlaw in a research report issued on Tuesday. They presently have a $19.00 price objective on the stock. Laidlaw’s price objective suggests a potential upside of 109.02% from the company’s current price.
Other equities analysts have also issued research reports about the company. TheStreet lowered Opko Health from a “hold” rating to a “sell” rating in a research note on Wednesday, November 9th. Zacks Investment Research lowered Opko Health from a “hold” rating to a “sell” rating in a research note on Wednesday, October 19th. Standpoint Research reiterated a “buy” rating on shares of Opko Health in a report on Friday. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Opko Health in a report on Monday, October 10th. Finally, Jefferies Group reiterated a “hold” rating and issued a $10.00 price objective on shares of Opko Health in a report on Monday, October 10th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $15.21.